Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > gottcha, Moosemeat....you're reading my posts as they're

<< Previous

Bullboard Posts

Next >>

Comment by NightHawk1987on May 18, 2020 4:52pm

72 Views

Post# 31043259

RE:RE:gottcha, Moosemeat....you're reading my posts as they're

Let's all leave the horse alone....you're just adding wood to the fire when you respond. He/she is just a over enthusiastic optimist. Nothing wrong with that. Just remove horse from your feed if you must. On a better note, today was a good sign for AGN. Lots of pressure built up. Pressure eventually has to release somewhere and sometime. Good things to come in the next 2 weeks. Just wait.

<< Previous

Bullboard Posts

Next >>

Victoria Gold stock falls 82% after Yukon landslide halts production